Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $18.9 million versus the consensus estimate of $16.71 million.

Company projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidance

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.